October 2025
1. BRAGA-NETO MB, Qazi T, Fulmer C, Holubar SD, et al
   Cellular and molecular mechanisms in the pathogenesis of pouchitis: more than just the microbiota.
   Gut. 2025;74:1905-1915.
   

   >> Share

   
   September 2025
2. 
   Correction: British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025.
   Gut. 2025 Sep 26:gutjnl-2024-334395corr1. doi: 10.1136/gutjnl-2024-334395.
   

   >> Share

   
   
3. ASHTON JJ, Green Z, Beattie RM
   British Society of Gastroenterology adult guidelines on inflammatory bowel disease: what can we learn for children and young people?
   Gut. 2025 Sep 12:gutjnl-2025-336739. doi: 10.1136/gutjnl-2025-336739.
   

   >> Share

   
   
4. HAZIME H, Ducasa GM, Santander AM, Brito N, et al
   DUOX2 activation drives bacterial translocation and subclinical inflammation in IBD-associated dysbiosis.
   Gut. 2025;74:1589-1601.
   

   >> Share

   
   
5. GONZALEZ-ACERA M, Patankar JV, Erkert L, Cineus R, et al
   Integrated multimodel analysis of intestinal inflammation exposes key molecular features of preclinical and clinical IBD.
   Gut. 2025;74:1602-1615.
   

   >> Share

   
   August 2025
6. MAHADEVAN U, Seow CH, Barnes EL, Chaparro M, et al
   Global consensus statement on the management of pregnancy in inflammatory bowel disease.
   Gut. 2025 Aug 28:gutjnl-2025-336402. doi: 10.1136/gutjnl-2025-336402.
   

   >> Share

   
   July 2025
7. MO M, Sun J, Mikulic I, Ludvigsson JF, et al
   Inflammatory bowel disease linked to accelerated cognitive decline in individuals with dementia: a nationwide cohort study.
   Gut. 2025 Jul 11:gutjnl-2025-335370. doi: 10.1136/gutjnl-2025-335370.
   

   >> Share

   
   
8. 
   Correction: Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
   Gut. 2025;74:e16.
   

   >> Share

   
   
9. KOU F, Li XY, Feng Z, Hua J, et al
   GPR171 restrains intestinal inflammation by suppressing FABP5-mediated Th17 cell differentiation and lipid metabolism.
   Gut. 2025;74:1279-1292.
   

   >> Share

   
   
10. BOURGONJE AR, Andreu-Sanchez S, Gacesa R, Innocenti G, et al
    Crohn's disease and ulcerative colitis exhibit prediagnostic antibody signatures with shared and divergent changes towards disease onset.
    Gut. 2025 Jul 2:gutjnl-2024-334362. doi: 10.1136/gutjnl-2024-334362.
    

    >> Share

    
    June 2025
11. PAL P, Mateen MA, Pooja K, Marri UK, et al
    Small intestinal contrast ultrasound versus imaging and enteroscopy in Crohn's disease.
    Gut. 2025 Jun 27:gutjnl-2025-335697. doi: 10.1136/gutjnl-2025-335697.
    

    >> Share

    
    
12. MORAN GW, Gordon M, Sinopolou V, Radford SJ, et al
    British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025.
    Gut. 2025;74.
    

    >> Share

    
    
13. SUN Y, Huang X, Zhang Y, Bao W, et al
    Enterococcus faecalis hijacks FABP2 to activate quorum-sensing signals and aggravate Crohn's disease by inducing gut dysbiosis.
    Gut. 2025 Jun 8:gutjnl-2024-334604. doi: 10.1136/gutjnl-2024-334604.
    

    >> Share

    
    
14. BARNICH N, Arthur JC, Buisson A, Campbell BJ, et al
    Adherent-invasive Escherichia coli in Crohn's disease: the 25th anniversary.
    Gut. 2025 Jun 5:gutjnl-2025-335331. doi: 10.1136/gutjnl-2025-335331.
    

    >> Share

    
    May 2025
15. ALKHATEB O, Ftouni R, Abbas O, Mourad FH, et al
    Skin lesions and chest pain in a patient with Crohn's disease.
    Gut. 2025 May 24:gutjnl-2025-335547. doi: 10.1136/gutjnl-2025-335547.
    

    >> Share

    
    
16. BLACKWELL J, Plevris N, Bancil A, Kobayashi T, et al
    Withdrawal of antitumour necrosis factor in patients with inflammatory bowel disease in remission: a randomised placebo-controlled clinical trial of GETECCU.
    Gut. 2025 May 13:gutjnl-2025-334946. doi: 10.1136/gutjnl-2025-334946.
    

    >> Share

    
    
17. PAL P, Mateen MA, Sekaran A, Pooja K, et al
    Can transperineal ultrasound replace endoscopic ultrasound in staging distal ulcerative colitis?
    Gut. 2025 May 13:gutjnl-2025-335681. doi: 10.1136/gutjnl-2025-335681.
    

    >> Share

    
    April 2025
18. EAST JE, Gordon M, Nigam GB, Sinopoulou V, et al
    British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease.
    Gut. 2025 Apr 30:gutjnl-2025-335023. doi: 10.1136/gutjnl-2025-335023.
    

    >> Share

    
    
19. TSCHURTSCHENTHALER M
    Dietary modulation of the gut phageome: a cross-kingdom dialogue in Crohn's disease.
    Gut. 2025 Apr 29:gutjnl-2025-335261. doi: 10.1136/gutjnl-2025-335261.
    

    >> Share

    
    
20. WAN Z, Hao X, Huang F, Dai H, et al
    Unravelling the causality between inflammatory bowel disease and polycystic ovary syndrome mediated by gut microbiota and blood metabolism: insights from two prospective cohort studies.
    Gut. 2025 Apr 19:gutjnl-2024-334693. doi: 10.1136/gutjnl-2024-334693.
    

    >> Share

    
    March 2025
21. SU R, Wen W, Jin Y, Cao Z, et al
    Dietary whey protein protects against Crohn's disease by orchestrating cross-kingdom interaction between the gut phageome and bacteriome.
    Gut. 2025 Mar 23:gutjnl-2024-334516. doi: 10.1136/gutjnl-2024-334516.
    

    >> Share

    
    
22. BAMIAS G, Menghini P, Pizarro TT, Cominelli F, et al
    Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD.
    Gut. 2025;74:652-668.
    

    >> Share

    
    February 2025
23. GUISADO D, Talware S, Wang X, Davis A, et al
    Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn's disease.
    Gut. 2025 Feb 17:gutjnl-2024-333558. doi: 10.1136/gutjnl-2024-333558.
    

    >> Share

    
    
24. GUDINO V, Bartolome-Casado R, Salas A
    Single-cell omics in inflammatory bowel disease: recent insights and future clinical applications.
    Gut. 2025 Feb 4:gutjnl-2024-334165. doi: 10.1136/gutjnl-2024-334165.
    

    >> Share

    
    January 2025
25. AL BAKIR I, Curtius K, Cresswell GD, Grant HE, et al
    Low-coverage whole genome sequencing of low-grade dysplasia strongly predicts advanced neoplasia risk in ulcerative colitis.
    Gut. 2025 Jan 29:gutjnl-2024-333353. doi: 10.1136/gutjnl-2024-333353.
    

    >> Share

    
    
26. BONFILS L, Poulsen G, Agrawal M, Julsgaard M, et al
    Impact of prenatal and postnatal maternal IBD status on offspring's risk of IBD: a population-based cohort study.
    Gut. 2025;74:206-213.
    

    >> Share

    
    
27. TE GROEN M, Wijnands AM, den Broeder N, de Jong DJ, et al
    Surveillance in inflammatory bowel disease: white light endoscopy with segmental re-inspection versus dye-based chromoendoscopy - a multi-arm randomised controlled trial (HELIOS).
    Gut. 2025 Jan 16:gutjnl-2024-333446. doi: 10.1136/gutjnl-2024-333446.
    

    >> Share

    
    December 2024
28. ZHANG J
    Dysbiosis exists in unaffected relatives of inflammatory bowel disease (IBD): emphasising the critical phases in the developmental trajectory of gut microbiota.
    Gut. 2024 Dec 23:gutjnl-2024-333425. doi: 10.1136/gutjnl-2024-333425.
    

    >> Share

    
    
29. GISBERT JP, Donday MG, Riestra S, Lucendo AJ, et al
    Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU.
    Gut. 2024 Dec 20:gutjnl-2024-333385. doi: 10.1136/gutjnl-2024-333385.
    

    >> Share

    
    
30. ADLER J, Gadepalli S, Rahman M, Kim S, et al
    Early tumour necrosis factor antagonist treatment prevents perianal fistula development in children with Crohn's disease: post hoc analysis of the RISK study.
    Gut. 2024 Dec 12:gutjnl-2024-333280. doi: 10.1136/gutjnl-2024-333280.
    

    >> Share

    
    
31. NEURATH MF, Sands BE, Rieder F
    Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?
    Gut. 2024;74:9-14.
    

    >> Share

    
    November 2024
32. AMIOT A, Seksik P, Meyer A, Stefanescu C, et al
    Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial.
    Gut. 2024 Nov 25:gutjnl-2024-333281. doi: 10.1136/gutjnl-2024-333281.
    

    >> Share

    
    
33. WELLENS J, Sabino J, Vanuytsel T, Tack J, et al
    Recent advances in clinical practice: mastering the challenge-managing IBS symptoms in IBD.
    Gut. 2024 Nov 12:gutjnl-2024-333565. doi: 10.1136/gutjnl-2024-333565.
    

    >> Share

    
    October 2024
34. LV X, Zeng Y, Ma W, Zheng Y, et al
    Novel mouse model for studying transmural intestinal fibrosis and creeping fat formation in stricturing Crohn's disease.
    Gut. 2024 Oct 14:gutjnl-2024-333590. doi: 10.1136/gutjnl-2024-333590.
    

    >> Share

    
    
35. VICH VILA A, Zhang J, Liu M, Faber KN, et al
    Untargeted faecal metabolomics for the discovery of biomarkers and treatment targets for inflammatory bowel diseases.
    Gut. 2024;73:1909-1920.
    

    >> Share

    
    September 2024
36. ERKERT L, Gamez-Belmonte R, Kabisch M, Schodel L, et al
    Alzheimer's disease-related presenilins are key to intestinal epithelial cell function and gut immune homoeostasis.
    Gut. 2024;73:1618-1631.
    

    >> Share

    
    
37. CARPAY N, de Boer NKH, Neefjes-Borst A, Bots S, et al
    Severe multiple therapy refractory colitis in a 46-year-old man.
    Gut. 2024;73:1617-1736.
    

    >> Share

    
    August 2024
38. ESTEVINHO MM, Midya V, Cohen-Mekelburg S, Allin KH, et al
    Emerging role of environmental pollutants in inflammatory bowel disease risk, outcomes and underlying mechanisms.
    Gut. 2024 Aug 30:gutjnl-2024-332523. doi: 10.1136/gutjnl-2024-332523.
    

    >> Share

    
    
39. PIERRE N, Huynh-Thu VA, Baiwir D, Mazzucchelli G, et al
    External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn's disease stopping infliximab.
    Gut. 2024 Aug 12:gutjnl-2024-332648. doi: 10.1136/gutjnl-2024-332648.
    

    >> Share

    
    
40. JACOBS JP, Spencer EA, Helmus DS, Yang JC, et al
    Age-related patterns of microbial dysbiosis in multiplex inflammatory bowel disease families.
    Gut. 2024 Aug 9:gutjnl-2024-332475. doi: 10.1136/gutjnl-2024-332475.
    

    >> Share

    
    
41. ATREYA R
    Glowing insights: tracking vedolizumab in the mucosa of patients with IBD via molecular endoscopy.
    Gut. 2024;73:1406-1408.
    

    >> Share

    
    
42. VERSTOCKT B, Vancamelbeke M, Vermeire S
    Increased inflammatory state in IBD multiplex first-degree relatives not developing intestinal disease.
    Gut. 2024;73:1586-1588.
    

    >> Share

    
    
43. MAJUMDER S, Santacroce G, Maeda Y, Zammarchi I, et al
    Endocytoscopy with automated multispectral intestinal barrier pathology imaging for assessment of deep healing to predict outcomes in ulcerative colitis.
    Gut. 2024 Aug 6:gutjnl-2024-332894. doi: 10.1136/gutjnl-2024-332894.
    

    >> Share

    
    July 2024
44. DAI C, Huang YH
    Rare cause of liver lesion in a patient with ulcerative colitis.
    Gut. 2024 Jul 20:gutjnl-2024-333095. doi: 10.1136/gutjnl-2024-333095.
    

    >> Share

    
    
45. HOV JR
    Sclerosing cholangitis and inflammatory bowel disease: a paradoxical relationship?
    Gut. 2024 Jul 17:gutjnl-2024-332835. doi: 10.1136/gutjnl-2024-332835.
    

    >> Share

    
    
46. ADOLPH TE, Meyer M, Jukic A, Tilg H, et al
    Heavy arch: from inflammatory bowel diseases to metabolic disorders.
    Gut. 2024;73:1376-1387.
    

    >> Share

    
    June 2024
47. DENNISON TW, Edgar RD, Payne F, Nayak KM, et al
    Patient-derived organoid biobank identifies epigenetic dysregulation of intestinal epithelial MHC-I as a novel mechanism in severe Crohn's Disease.
    Gut. 2024 Jun 10:gutjnl-2024-332043. doi: 10.1136/gutjnl-2024-332043.
    

    >> Share

    
    
48. IACUCCI M, Santacroce G, Majumder S, Morael J, et al
    Opening the doors of precision medicine: novel tools to assess intestinal barrier in inflammatory bowel disease and colitis-associated neoplasia.
    Gut. 2024 Jun 8:gutjnl-2023-331579. doi: 10.1136/gutjnl-2023-331579.
    

    >> Share

    
    
49. LIN S, Wang J, Mukherjee PK, Mao R, et al
    Milk fat globule-epidermal growth factor 8 (MFGE8) prevents intestinal fibrosis.
    Gut. 2024;73:1110-1123.
    

    >> Share

    
    
50. BEDKE T, Stumme F, Tomczak M, Steglich B, et al
    Protective function of sclerosing cholangitis on IBD.
    Gut. 2024 Jun 5:gutjnl-2023-330856. doi: 10.1136/gutjnl-2023-330856.
    

    >> Share

    
    
51. HONAP S, Jairath V, Sands BE, Dulai PS, et al
    Acute severe ulcerative colitis trials: the past, the present and the future.
    Gut. 2024 Jun 4:gutjnl-2024-332489. doi: 10.1136/gutjnl-2024-332489.
    

    >> Share

    
    May 2024
52. MONAGHAN TM, Ugun-Klusek A, Finelli M, Gurnani P, et al
    Connecting inflammatory bowel and neurodegenerative diseases: microRNAs as a shared therapeutic intervention.
    Gut. 2024;73:1034-1036.
    

    >> Share

    
    April 2024
53. GABRIELS RY, van der Waaij AM, Linssen MD, Dobosz M, et al
    Fluorescently labelled vedolizumab to visualise drug distribution and mucosal target cells in inflammatory bowel disease.
    Gut. 2024 Apr 5:gutjnl-2023-331696. doi: 10.1136/gutjnl-2023-331696.
    

    >> Share

    
    
54. RIEDER F, Mukherjee PK, Massey WJ, Wang Y, et al
    Fibrosis in IBD: from pathogenesis to therapeutic targets.
    Gut. 2024;73:854-866.
    

    >> Share

    
    
55. KARMI N, Sun S, Festen EAM, Vich Vila A, et al
    Gut microbial metabolism of 5-aminosalicylic acid in inflammatory bowel disease.
    Gut. 2024 Apr 3:gutjnl-2024-332205. doi: 10.1136/gutjnl-2024-332205.
    

    >> Share

    
    March 2024
56. ANANTHAKRISHNAN AN
    Inflammatory bowel diseases: are we ready to recommend a preventive diet for infants?
    Gut. 2024;73:559-560.
    

    >> Share

    
    
57. SCHULZ-KUHNT A, Ruhle K, Javidmehr A, Dobronti M, et al
    ATP citrate lyase (ACLY)-dependent immunometabolism in mucosal T cells drives experimental colitis in vivo.
    Gut. 2024;73:601-612.
    

    >> Share

    
    February 2024
58. ABDELRAHIM M, Siggens K, Iwadate Y, Maeda N, et al
    New AI model for neoplasia detection and characterisation in inflammatory bowel disease.
    Gut. 2024 Feb 23:gutjnl-2023-330718. doi: 10.1136/gutjnl-2023-330718.
    

    >> Share

    
    
59. ZHANG L, Agrawal M, Ng SC, Jess T, et al
    Early-life exposures and the microbiome: implications for IBD prevention.
    Gut. 2024;73:541-549.
    

    >> Share

    
    
60. ADOLPH TE
    It is in the matrix: a molecular clue to fibro-stenotic Crohn's disease.
    Gut. 2024 Feb 20:gutjnl-2024-332016. doi: 10.1136/gutjnl-2024-332016.
    

    >> Share

    
    
61. AN H, Zhong M, Gan H
    Proton pump inhibitors and the risk of inflammatory bowel disease: a Mendelian randomisation study.
    Gut. 2024 Feb 15:gutjnl-2024-331904. doi: 10.1136/gutjnl-2024-331904.
    

    >> Share

    
    January 2024
62. GUO A, Ludvigsson J, Brantsaeter AL, Klingberg S, et al
    Early-life diet and risk of inflammatory bowel disease: a pooled study in two Scandinavian birth cohorts.
    Gut. 2024 Jan 30:gutjnl-2023-330971. doi: 10.1136/gutjnl-2023-330971.
    

    >> Share

    
    
63. SUN J, Yao J, Olen O, Halfvarson J, et al
    Familial coaggregation of inflammatory bowel disease with cardiovascular disease: a nationwide multigenerational cohort study.
    Gut. 2024 Jan 6:gutjnl-2023-331632. doi: 10.1136/gutjnl-2023-331632.
    

    >> Share

    
    
64. CHIRIAC MT, Hracsko Z, Gunther C, Gonzalez-Acera M, et al
    IL-20 controls resolution of experimental colitis by regulating epithelial IFN/STAT2 signalling.
    Gut. 2024;73:282-297.
    

    >> Share

    
    December 2023
65. ERIKSEN C, Danneskiold-Samsoe NB, Moll JM, Myers PN, et al
    Specific gut pathobionts escape antibody coating and are enriched during flares in patients with severe Crohn's disease.
    Gut. 2023 Dec 16:gutjnl-2023-330677. doi: 10.1136/gutjnl-2023-330677.
    

    >> Share

    
    
66. MINERVINA AA, Pogorelyy MV, Paysen S, Luening U, et al
    Crohn's-associated invariant T cells (CAITs) recognise small sulfonate molecules on CD1d.
    Gut. 2023;73:205-206.
    

    >> Share

    
    November 2023
67. TUN HM, Peng Y, Massimino L, Sin ZY, et al
    Gut virome in inflammatory bowel disease and beyond.
    Gut. 2023 Nov 10:gutjnl-2023-330001. doi: 10.1136/gutjnl-2023-330001.
    

    >> Share

    
    
68. ULLRICH KA, Derdau J, Baltes C, Battistella A, et al
    IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells.
    Gut. 2023;72:2081-2094.
    

    >> Share

    
    October 2023
69. MUKHOPADHYA I
    Is HBx protein the X factor in the pathogenesis of IBD?
    Gut. 2023;72:1808-1809.
    

    >> Share

    
    September 2023
70. MA Y, Zhang X, Xuan B, Li D, et al
    Disruption of CerS6-mediated sphingolipid metabolism by FTO deficiency aggravates ulcerative colitis.
    Gut. 2023 Sep 21:gutjnl-2023-330009. doi: 10.1136/gutjnl-2023-330009.
    

    >> Share

    
    
71. JIANG L, Li JC, Shen L, Tang BS, et al
    Association between inflammatory bowel disease and Alzheimer's disease: multivariable and bidirectional Mendelian randomisation analyses.
    Gut. 2023;72:1797-1799.
    

    >> Share

    
    
72. CHURCHHOUSE AM, Moffat VE, Selinger CP, Lamb CA, et al
    British Society of Gastroenterology interim framework for addressing the COVID-19-related backlog in inflammatory bowel disease colorectal cancer surveillance.
    Gut. 2023;72:1631-1634.
    

    >> Share

    
    August 2023
73. SCHWARZLER J, Zollner A, Dolejsi T, Mayr L, et al
    Inflammatory bowel disease in STAT1 gain-of-function immunodeficiency treated with precision medicine.
    Gut. 2023 Aug 24:gutjnl-2023-330588. doi: 10.1136/gutjnl-2023-330588.
    

    >> Share

    
    
74. CHETWOOD JD, Paramsothy S, Haifer C, Leong RW, et al
    Key metabolomic alterations are associated with ulcerative colitis disease state and activity: a validation analysis.
    Gut. 2023 Aug 17:gutjnl-2023-330196. doi: 10.1136/gutjnl-2023-330196.
    

    >> Share

    
    
75. WAUTERS L, Tito RY, Ceulemans M, Outtier A, et al
    Microbiome variance of the small bowel in Crohn's disease.
    Gut. 2023;72:1626-1628.
    

    >> Share

    
    July 2023
76. BECKER C, Adolph TE
    Disentangling tryptophan metabolism in inflammatory bowel diseases.
    Gut. 2023;72:1235-1236.
    

    >> Share

    
    
77. LEE JC
    Going deeper: molecular inflammatory scores in IBD.
    Gut. 2023;72:1233-1234.
    

    >> Share

    
    
78. MICHAUDEL C, Danne C, Agus A, Magniez A, et al
    Rewiring the altered tryptophan metabolism as a novel therapeutic strategy in inflammatory bowel diseases.
    Gut. 2023;72:1296-1307.
    

    >> Share

    
    
79. ARGMANN C, Hou R, Ungaro RC, Irizar H, et al
    Biopsy and blood-based molecular biomarker of inflammation in IBD.
    Gut. 2023;72:1271-1287.
    

    >> Share

    
    June 2023
80. DE BOER NKH, Simsek M, Meijer B, Neurath MF, et al
    Drug rediscovery in gastroenterology: from off-label to on-label use of thioguanine in inflammatory bowel disease.
    Gut. 2023 Jun 28:gutjnl-2023-329679. doi: 10.1136/gutjnl-2023-329679.
    

    >> Share

    
    
81. LOPETUSO LR, Deleu S, Godny L, Petito V, et al
    The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease.
    Gut. 2023 Jun 20:gutjnl-2023-329948. doi: 10.1136/gutjnl-2023-329948.
    

    >> Share

    
    
82. SCHWARZFISCHER M, Niechcial A, Handler K, Morsy Y, et al
    TiO(2) nanoparticles abrogate the protective effect of the Crohn's disease-associated variation within the PTPN22 gene locus.
    Gut. 2023;72:1101-1114.
    

    >> Share

    
    
83. MILLET V, Gensollen T, Maltese M, Serrero M, et al
    Harnessing the Vnn1 pantetheinase pathway boosts short chain fatty acids production and mucosal protection in colitis.
    Gut. 2023;72:1115-1128.
    

    >> Share

    
    
84. DANNE C, Michaudel C, Skerniskyte J, Planchais J, et al
    CARD9 in neutrophils protects from colitis and controls mitochondrial metabolism and cell survival.
    Gut. 2023;72:1081-1092.
    

    >> Share

    
    May 2023
85. PAL P, Ramchandani M, Banerjee R, Viswakarma P, et al
    Technical performance and diagnostic yield of motorised spiral enteroscopy compared with single-balloon enteroscopy in suspected Crohn's disease: a randomised controlled, open-label study (the MOTOR-CD trial).
    Gut. 2023 May 17:gutjnl-2023-329885. doi: 10.1136/gutjnl-2023-329885.
    

    >> Share

    
    
86. LU H, Zhang C, Wu W, Chen H, et al
    MCPIP1 restrains mucosal inflammation by orchestrating the intestinal monocyte to macrophage maturation via an ATF3-AP1S2 axis.
    Gut. 2023;72:882-895.
    

    >> Share

    
    
87. ZUO L, Kuo WT, Cao F, Chanez-Paredes SD, et al
    Tacrolimus-binding protein FKBP8 directs myosin light chain kinase-dependent barrier regulation and is a potential therapeutic target in Crohn's disease.
    Gut. 2023;72:870-881.
    

    >> Share

    
    April 2023
88. GHATE A, Uhlig HH
    Defective microbial sensing and clearance in perianal Crohn's disease: a role for complement factor B.
    Gut. 2023 Apr 25:gutjnl-2023-329801. doi: 10.1136/gutjnl-2023-329801.
    

    >> Share

    
    
89. AKHLAGHPOUR M, Haritunians T, More SK, Thomas LS, et al
    Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis.
    Gut. 2023 Apr 20:gutjnl-2023-329689. doi: 10.1136/gutjnl-2023-329689.
    

    >> Share

    
    
90. ZHAO J, Chen J, Sun Y, Yuan S, et al
    Defining gene-lifestyle interactions in inflammatory bowel disease: progress towards understanding disease pathogenesis.
    Gut. 2023 Apr 4:gutjnl-2023-329875. doi: 10.1136/gutjnl-2023-329875.
    

    >> Share

    
    
91. YE BD
    Proton pump inhibitors and the risk of inflammatory bowel disease: cause, protopathic bias or others?
    Gut. 2023 Apr 4:gutjnl-2023-329506. doi: 10.1136/gutjnl-2023-329506.
    

    >> Share

    
    
92. HSU NY, Nayar S, Gettler K, Talware S, et al
    NOX1 is essential for TNFalpha-induced intestinal epithelial ROS secretion and inhibits M cell signatures.
    Gut. 2023;72:654-662.
    

    >> Share

    
    
93. AGRAWAL M, Poulsen G, Colombel JF, Allin KH, et al
    Maternal antibiotic exposure during pregnancy and risk of IBD in offspring: a population-based cohort study.
    Gut. 2023;72:804-805.
    

    >> Share

    
    March 2023
94. FAYE AS, Jess T
    Antibiotic use and inflammatory bowel disease: number needed to harm? Authors' reply.
    Gut. 2023 Mar 27:gutjnl-2023-329851. doi: 10.1136/gutjnl-2023-329851.
    

    >> Share

    
    
95. VICH VILA A, Hu S, Andreu-Sanchez S, Collij V, et al
    Faecal metabolome and its determinants in inflammatory bowel disease.
    Gut. 2023 Mar 23:gutjnl-2022-328048. doi: 10.1136/gutjnl-2022-328048.
    

    >> Share

    
    
96. LAUBE R, Selinger CP, Seow CH, Christensen B, et al
    Australian inflammatory bowel disease consensus statements for preconception, pregnancy and breast feeding.
    Gut. 2023 Mar 21:gutjnl-2022-329304. doi: 10.1136/gutjnl-2022-329304.
    

    >> Share

    
    
97. ZHANG E, Nguyen THO, Allen LF, Kedzierski L, et al
    Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments.
    Gut. 2023 Mar 6:gutjnl-2022-329136. doi: 10.1136/gutjnl-2022-329136.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share